Usage: DDAVP Tablets are indicated for managing central diabetes insipidus and controlling temporary polyuria and polydipsia post-head trauma or surgery. They are also used to treat primary nocturnal enuresis, either alone or alongside behavioral interventions.
Usage: REBYOTA is indicated for preventing the recurrence of Clostridioides difficile infection (CDI) in adults aged 18 and older after antibiotic treatment for recurrent CDI. It is not intended for the treatment of CDI.